Anti-Human CD30/TNFRSF8 Reference Antibody (MDX-1401, RUO) (HB038046)

Name: Anti-Human CD30/TNFRSF8 Reference Antibody (MDX-1401, RUO)
Brand: abinScience
SKU: HB038046
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HB038046
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	MDX-1401
Actividad biológica	MDX-1401 binds to recombinant CD30 with a K d value of 0.83 nmol/L, exhibiting binding affinity comparable to that of its parental antibody MDX-060 [1]. MDX-1401 (125 I-MDX-1401) binds to CD30 on the surface of the Hodgkin's lymphoma cell line L540 cells, with a K d value of approximately 1.9 nmol/L [1]. MDX-1401 (0.012-50 ug/mL; 30 min primary incubation, 30 min secondary incubation) binds to CD30 + lymphoma cell lines (L540, Karpas-299, L428, L1236) in a dose-dependent manner, and its binding properties are consistent with those of the parental antibody MDX-060 [1]. MDX-1401 mediates FcγRIIIa-dependent antibody-dependent cellular cytotoxicity (ADCC) against L540 Hodgkin lymphoma cells, with an EC 50 of 0.009 ug/mL and a maximum cell lysis rate of 87%, exhibiting superior potency and efficacy compared to the parental antibody MDX-060 [1]. MDX-1401 (treated at 37°C for 4 h) mediates dose-dependent ADCC against CD30 + lymphoma cell lines (L540, Karpas-299, L428, L1236), with EC 50 values ranging from 0.008 to 0.04 ug/mL and maximum lysis rates of 13% to 68%. This includes activity against L1236 cells with low CD30 expression, against which the parental antibody MDX-060 shows no activity [1]. MDX-1401 binds to CD30 on L540 Hodgkin lymphoma cells with a K D value of 1.9 nM, and its antigen-binding affinity is nearly identical to that of its parental antibody MDX-060 (K D ~1.4 nM) [2]. MDX-1401 mediates significantly stronger and more effective ADCC against CD30-expressing tumor cell lines (including those with low CD30 expression) across all FcgRIIIa polymorphic variants, with a decreased EC 50 and an increased maximum specific lysis rate compared to its parental antibody [2]. MDX-1401 (1 mg/kg; i.p.; single dose) significantly prolongs the survival of SCID mice with systemic Karpas-299 ALCL [1].
Sistema de expresión	Mammalian cells
Objetivo	CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P28908
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	MDX-1401, MDX1401, MDX1401
Fondo	Tumor necrosis factor receptor superfamily member 8 (CD30/TNFRSF8) is a ~63 kDa protein. Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. CD30 is the therapeutic target of brentuximab vedotin (Adcetris). 1. Smith, CA. et al. (1993) Cell 73, 1349-60. PMID: 8391931 2. Aizawa, S. et al. (1997) The Journal of biological chemistry 272, 2042-5. PMID: 8999898
Referencias	1. Cardarelli PM, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res. 2009;15(10):3376-3383. [HB038046] 2. Cardarelli P M, et al. Characterization of MDX-1401, a Human Anti-CD30 Antibody with Enhanced Effector Function, for Therapy of Malignant Lymphoma[J]. Blood, 2008, 112(11): 1580. [HB038046] 3. Foyil KV, et al. Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep. 2010;5(3):140-147. [HB038046]
Nota	For research use only. Not suitable for clinical or therapeutic use.